{
  "meta": {
    "title": "17_Porphyrins_And_Bile_Pigments",
    "url": "https://brainandscalpel.vercel.app/17-porphyrins-and-bile-pigments-a9a1c624.html",
    "scrapedAt": "2025-11-30T12:26:36.883Z"
  },
  "questions": [
    {
      "text": "What is the porphyrin present in heme?",
      "choices": [
        {
          "id": 1,
          "text": "Protoporphyrin"
        },
        {
          "id": 2,
          "text": "Uroporphyrin"
        },
        {
          "id": 3,
          "text": "Coproporphyrin"
        },
        {
          "id": 4,
          "text": "Benzoporphyrin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div class=\"page\" title=\"Page 336\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The porphyrin present in heme is<strong> protoporphyrin</strong>.</p>\n<p>Heme is <strong>ferroprotoporphyrin</strong>. Iron is present in the <strong>ferrous </strong>(Fe<sup>2+</sup>) state in heme. Porphyrins are <strong>cyclic</strong> <strong>coloured compounds</strong> formed by the linkage of<strong> four pyrrole rings</strong> through <strong>methyne </strong>or <strong>methenyl</strong> (=CH-) bridges. There are three types of porphyrins:</p>\n<ul>\n<li>Uroporphyrin (most water-soluble).</li>\n<li>Coproporphyrin (intermediate).</li>\n<li>Protoporphyrin (least water-soluble).</li>\n</ul>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Heme containing proteins</h3><table>\n<tbody>\n<tr>\n<td><strong>Protein</strong></td>\n<td><strong>Function</strong></td>\n</tr>\n<tr>\n<td>&nbsp;Hemoglobin</td>\n<td>&nbsp; Transport of oxygen in the blood</td>\n</tr>\n<tr>\n<td>&nbsp;Myoglobin</td>\n<td>&nbsp; Storage of oxygen in muscle</td>\n</tr>\n<tr>\n<td>&nbsp;Cytochrome C</td>\n<td>&nbsp; Involvement in the electron transport chain</td>\n</tr>\n<tr>\n<td>&nbsp;Cytochrome P450</td>\n<td>&nbsp;Hydroxylation of xenobiotics</td>\n</tr>\n<tr>\n<td>&nbsp;Catalase</td>\n<td>&nbsp;Degradation of hydrogen peroxide</td>\n</tr>\n<tr>\n<td>&nbsp;Tryptophan pyrrolase</td>\n<td>&nbsp;Oxidation of tryptophan</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0672",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a site for heme synthesis?",
      "choices": [
        {
          "id": 1,
          "text": "Osteocyte"
        },
        {
          "id": 2,
          "text": "Liver"
        },
        {
          "id": 3,
          "text": "Erythroid cells of bone marrow"
        },
        {
          "id": 4,
          "text": "Mature erythrocyte"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Mature erythrocyte</strong> is <strong>not</strong> a site for <strong>heme biosynthesis</strong>.</p>\n<p>Approximately 85% of heme synthesis occurs in <strong>erythroid precursor cells</strong> in the<strong> bone marrow</strong> and the majority of the remainder in <strong>hepatocytes. </strong>Heme biosynthesis<strong> </strong>occurs both in<strong> mitochondria </strong>and <strong>cytoplasm</strong>.<strong> </strong>It is<strong> </strong>initiated<strong> </strong>by the <strong>condensation </strong>of<strong> succinyl–CoA </strong>and<strong> glycine </strong>in a reaction catalyzed by<strong> mitochondrial ALA synthase. </strong>This initial reaction,<strong> </strong>and the last three steps in the formation of heme occur in mitochondria, whereas the intermediate steps of the biosynthetic pathway occur in the<strong> </strong>cytosol.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6066fe3cc6dd4a2fb2cb28da8566b7dbx1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0701",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following TCA cycle intermediate is a part of heme metabolism?<div class='question-desc-html'><p>(TCA - tricarboxylic acid)</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Alpha ketoglutarate"
        },
        {
          "id": 2,
          "text": "Fumarate"
        },
        {
          "id": 3,
          "text": "Succinyl CoA"
        },
        {
          "id": 4,
          "text": "Malate"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>Succinyl Co-A</strong>, an essential part for heme biosynthesis, is an intermediate of the TCA cycle.</span></div>\n<div> </div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">The synthesis of heme begins by condensation of </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>succinyl Co-A </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">and </span><strong>glycine</strong> to<span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"> form </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>α-amino-β-ketoadipate, </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">which is then converted to </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>δ-aminolevulinate. </strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">These steps are mediated by the enzyme </span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>ALA synthase </strong>in the mitochrondria. </span></div>\n<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Various steps involved in the synthesis of heme is illustrated in the image given below:</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/edbc8f1df9b5418bbd390e37a5f8dab7x1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7669",
      "difficulty": "easy"
    },
    {
      "text": "Which step of heme synthesis requires pyridoxal phosphate?<div class='question-desc-html'><p>(ALA - α aminolevulinate)</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Succinyl CoA to α-amino-β-ketoadipate"
        },
        {
          "id": 2,
          "text": "α-Amino-β-ketoadipate to ALA"
        },
        {
          "id": 3,
          "text": "ALA to porphobilinogen"
        },
        {
          "id": 4,
          "text": "Porphobilinogen to hydroxymethylbilane"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Conversion of <strong>succinyl CoA</strong> to <strong>α-amino-β-ketoadipate</strong> requires <strong>pyridoxal phosphate</strong>.</p>\n<p>The first step of heme synthesis is the conversion of succinyl CoA to α-amino-β-ketoadipate. This reaction is dependent on pyridoxal phosphate. α-amino-β-ketoadipate is rapidly <strong>decarboxylated </strong>to produce<strong> δ -aminolevulinate</strong>. It is catalyzed by <strong>mitochondrial ALA synthase. </strong></p>\n<p class=\"p1\">Succinyl-CoA <span class=\"s1\">+ </span> glycine <span class=\"s1\">→ α-amino-β-keto</span>adipate <span class=\"s1\">+ </span> CoA-SH <span class=\"s1\">→ </span><span class=\"s1\">δ</span>-aminolevulinate <span class=\"s1\">+ </span> CO<sub><span class=\"s2\">2</span> </sub></p>\n<p class=\"p1\"><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Various steps involved in the synthesis of heme is illustrated in the image given below:</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/246c860ce00646838d126a7db1de2f8bx1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0702",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the rate-limiting enzyme in the hepatic biosynthesis of heme?<div class='question-desc-html'><p>(ALA - α- aminolevulinate)</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "ALA Synthase"
        },
        {
          "id": 2,
          "text": "Uroporphyrinogen III synthase"
        },
        {
          "id": 3,
          "text": "ALA dehydratase"
        },
        {
          "id": 4,
          "text": "Ferrochelatase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>rate-limiting enzyme</strong> in the hepatic biosynthesis of heme is mitochondrial <strong>ALA synthase. </strong></p>\n<p>ALA synthase (ALAS) is a<strong> mitochondrial </strong>enzyme catalysing the conversion of succinyl CoA and glycine to ALA. There are two isozymes of ALA synthase. <strong>ALAS-1</strong> is expressed throughout the body. It is <strong>induced</strong> by drugs whose metabolism requires<strong> cytochromes </strong>(hemoprotein). <strong>Heme, </strong>probably acting through an <strong>aporepressor</strong> molecule, acts as a<strong> negative regulator </strong>of the synthesis of<strong> </strong>ALAS-1<strong> </strong>i.e. ALAS-1 synthesis decreases in the presence of heme. </p>\n<p><strong>ALAS-2</strong> is expressed in the <strong>erythrocyte precursor cells. </strong>It is neither induced by drugs<strong> </strong>nor is its feedback regulated by heme.<strong><br /></strong></p>\n<p> </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0a039fd29e264b72a94ddbcd4cf40f94x1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0706",
      "difficulty": "easy"
    },
    {
      "text": "A 44-year-old man with a past medical history of acute intermittent porphyria is planned for neurosurgery. Considering the risk of potential complications, the anaesthetist decides not to use barbiturates for induction.  What is the biochemical basis behind the worsening of porphyria by barbiturates?",
      "choices": [
        {
          "id": 1,
          "text": "Repression of ALA synthase"
        },
        {
          "id": 2,
          "text": "De-repression of ALA synthase"
        },
        {
          "id": 3,
          "text": "Inhibiton of ferrochelatase"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The biochemical basis of <strong>worsening </strong>of porphyria by <strong>barbiturates</strong> is due to de-repression of <strong>ALA synthase. </strong>De-repression is the removal of repression of an enzyme, or the induction of a blocked enzyme.</p>\n<p>Barbiturates are metabolized by<strong> microsomal CYP450, </strong>a <strong>heme-protein oxidase</strong> system found in the liver. In patients with porphyria, barbiturates <strong>precipitate</strong> an attack of <strong>porphyria </strong>by the following mechanism:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/920bb948896549ca8d154dc6b5f5166cx1280x1313.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0707",
      "difficulty": "medium"
    },
    {
      "text": "A young patient came with complaints of acute abdominal pain on and off and tingling sensation of limbs and at times weakness of limbs. She had a history of eating paint from the wall of a newly built house.  Which of the following enzyme defect will be the cause of her condition?",
      "choices": [
        {
          "id": 1,
          "text": "ALA synthase"
        },
        {
          "id": 2,
          "text": "ALA dehydratase"
        },
        {
          "id": 3,
          "text": "Heme synthase"
        },
        {
          "id": 4,
          "text": "Coproporphyrinogen oxidase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>A child with acute abdominal pain, tingling sensation and weakness of limbs with history of eating paint likely has <strong>lead poisoning.</strong> It is characterized by impaired <strong>ALA dehydratase </strong>enzyme activity.</p>\n<p>Lead is a potent<strong> inhibitor</strong> of both<strong> ALA dehydratase</strong> and <strong>ferrochelatase</strong>/<strong> </strong>heme synthase (option C). However, it has the greatest inhibitory action on ALA dehydratase. Lead poisonining thus leads to the buildup of protoporphyrin and ALA. Lead also substitutes for <strong>calcium</strong> in many fundamental cellular processes. It can cross red blood cell membranes as well as the blood-brain barrier and enter the <strong>neuroglial cells</strong> which support brain function. The <strong>fatal dose </strong>of lead is<strong> 20g </strong>of lead acetate and the <strong>fatal period </strong>is 1 to 2 days.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b98b5f3f140340c3be0a305fa0fd4771x1280x1525.JPEG\" alt=\"Explanation Image\"><p>Other options: </p>\n<p>Option A: <strong>ALA synthase 2 </strong>defect causes X-linked protoporphyria. <br />Option C: <strong>Heme synthase</strong>, or ferrochelatase, defect causes erythropoeitic protoporphyria. <br />Option D: <strong>Coproporphyrinogen oxidase </strong>defect causes hereditary corproporphyria.</p><hr><h3>Related Pearl: Lead Poisoning/Plumbism/Saturnism</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Lead Toxicity</strong></td>\n</tr>\n<tr>\n<td>Source of exposure</td>\n<td>\n<p>Occupational exposure</p>\n<p>Lead paint</p>\n</td>\n</tr>\n<tr>\n<td>Route of absorption</td>\n<td>\n<p>Children - GI tract</p>\n<p>Adults - Respiratory tract</p>\n</td>\n</tr>\n<tr>\n<td>Mechanism of action</td>\n<td>\n<ul>\n<li>Binds to sulfhydryl groups and inhibits\n<ul>\n<li>ALA dehydratase</li>\n<li>Ferrochelatase</li>\n</ul>\n</li>\n<li>Inhibits pyrimidine 5' nucleotidase</li>\n<li>Competes with <strong>calcium</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Organs affected <strong>(acute</strong> toxicity)</td>\n<td>\n<p>GI tract, Bone marrow, Peripheral nerves</p>\n</td>\n</tr>\n<tr>\n<td>Organs affected <strong>(chronic</strong> toxicity)</td>\n<td>\n<p>CNS, Kidney</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Characteristic clinical findings</p>\n<p><strong>(ABCDEF)</strong></p>\n</td>\n<td>\n<p><strong>A - </strong>Anemia with basophilic stippling</p>\n<p><strong>B - </strong>Burtonian line (blue stippled line on gums)</p>\n<p><strong>C - </strong>Constipation and colic (abdominal pain)</p>\n<p><strong>D - </strong>Drop (wrist and foot drop) due to neuropathy</p>\n<p><strong>E - </strong>Encephalopathy- <strong>Mostly seen in infants</strong> presenting with severe ataxia, vomiting, lethargy, stupor, convulsions, and coma</p>\n<p><strong>F - Facial pallor (Earliest sign)</strong></p>\n</td>\n</tr>\n<tr>\n<td>Diagnosis</td>\n<td>Blood lead levels</td>\n</tr>\n<tr>\n<td>Treatment</td>\n<td>Calcium EDTA; succimer(DMSA)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9490",
      "difficulty": "medium"
    },
    {
      "text": "What is the by-product of the ​reaction catalyzed by cytosolic hydroxymethylbilane synthase in heme synthesis?",
      "choices": [
        {
          "id": 1,
          "text": "H2O"
        },
        {
          "id": 2,
          "text": "NH3"
        },
        {
          "id": 3,
          "text": "CO2"
        },
        {
          "id": 4,
          "text": "CoA.SH"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The by-product of the reaction catalyzed by cytosolic <strong>hydroxymethylbilane</strong> (HMB)<strong> synthase</strong> in heme synthesis is <strong>ammonia </strong>(NH<sub>3</sub>). </p>\n<p>HMB synthase is also known as<strong> porphobilinogen deaminase </strong>or <strong>uroporphyrinogen 1 synthase.</strong> It catalyses the <strong>condensation</strong> of 4 molecules of porphobilinogen to release hydroxymethylbilane and <strong>4 molecules </strong>of NH<sub>3</sub>. </p>\n<p>4 Porphobilinogen + H<sub>2</sub>O -------&gt; Hydroxymethylbilane + 4 NH<sub>3</sub></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/23fbcc01b1044a7288535162a28e7fb2x1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0704",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following enzymes catalyzes the cyclization of hydroxymethylbilane?",
      "choices": [
        {
          "id": 1,
          "text": "Uroporphyrinogen I synthase"
        },
        {
          "id": 2,
          "text": "Uroporphyrinogen II synthase"
        },
        {
          "id": 3,
          "text": "Uroporphyrinogen III synthase"
        },
        {
          "id": 4,
          "text": "Uroporphyrinogen decarboxylase"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Cyclization of hydroxymethylbilane (HMB) is catalyzed by<strong> uroporphyrinogen III synthase</strong></p>\n<p>HMB is cyclised to <strong>uroporphyrinogen III </strong>by uroporphyrinogen III synthase. Uroporphyrinogen III is the <strong>first</strong> porphyrin precursor in heme synthesis.</p>\n<p><strong>Note:</strong> HMB can also <strong>cyclize spontaneously</strong> to form <strong>uroporphyrinogen I. </strong>But under normal circumstances, the porphyrinogen formed is predominantly uroporphyrinogen III. </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c4af0c95a747437691a21bb5a71efed9x1280x1732.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0705",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following porphyrias is not inherited in an autosomal dominant mode?",
      "choices": [
        {
          "id": 1,
          "text": "Erythropoietic protoporphyria"
        },
        {
          "id": 2,
          "text": "Variegate porphyria"
        },
        {
          "id": 3,
          "text": "Acute intermittent porphyria"
        },
        {
          "id": 4,
          "text": "Hereditary coproporphyria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Erythropoietic protoporphyria </strong>is <strong>not</strong> transmitted in an <strong>autosomal dominant</strong> manner..</p>\n<p>Erythryopoietic protoporphyria is an <strong>autosomal recessive</strong> disease caused by a defect in<strong> </strong>the enzyme<strong> ferrochelatase </strong>(FECH).<strong> </strong>It is the <strong>most common</strong> porphyria in<strong> children</strong>, who present with <strong>n</strong><strong>on-blistering photosensitivity. </strong>An increase in the ratio of<strong> </strong>free protoporphyrin to zinc bound porphyrin in erythrocytes is the hallmark of this disease. The diagnosis is made by <strong>FECH mutation analysis</strong>.</p>\n<p><strong>Note:</strong> Most porphyrias are<strong> </strong>autosomal dominant <strong>except</strong>:</p>\n<ul>\n<li>ALA dehydratase deficiency porphyria - autosomal recessive</li>\n<li>Congenital erythropoietic porphyria - autosomal recessive</li>\n<li>Erythropoietic protoporphyria - autosomal recessive</li>\n<li>X-linked protoporphyria</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0723",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old man presents with a history of fatigue, dark-coloured urine and photosensitivity. He consumes alcohol regularly. On examination, hyperpigmentation and scarring are present on the face and dorsum of the hand. Lab findings are given below. Which of the following is the most likely diagnosis?<div class='question-desc-html'><p>Hb: 7.4 mg/dl<br />Peripheral blood picture: Suggestive of microcytic hypochromic anaemia<br />Urinary porphobilinogen level: Normal<br />Urinary uroporphyrin level: Increased</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Acute intermittent porphyria"
        },
        {
          "id": 2,
          "text": "Porphyria cutanea tarda"
        },
        {
          "id": 3,
          "text": "Hereditary coproporphyria"
        },
        {
          "id": 4,
          "text": "Variegate porphyria"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>A middle-aged adult presenting with features of hemolysis and photosensitivity with elevated urine uroporphyrin suggests a diagnosis of<strong> porphyria cutanea tarda.</strong></p>\n<p>Porphyria cutanea tarda (PCT) is the<strong> most common </strong>porphyria. It is caused by the deficiency of <strong>uroporphyrinogen</strong> decarboxylase, which converts uroporphyrinogen III to coproporphyrinogen III.  It is characterized by photosensivity, which manifests as <strong>blistering skin lesions</strong> on the back of the hands with crusting and scarring. It is associated with <strong>hemochromatosis </strong>and patients may develop <strong>chronic liver disease.</strong> There is increased excretion of <strong>uroporphyrin</strong> in the urine.</p><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0708",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged female patient presented with intermittent abdominal pain, nausea, vomiting, constipation and bilateral lower limb numbness for 3 days. On examination, she is thin and pale. Her vitals and lab findings are given below. Which of the following is the most likely diagnosis?<div class='question-desc-html'><p>BP: 160/90 mmHg, Heart rate: 130 bpm<br />Haemoglobin: 8.2 mg/dl<br />Peripheral blood picture: Normal morphology<br />Serum ferritin: Elevated<br /><span>Urinary aminolevulinic acid and porphobilinogen level: Increased; urine sample turned dark brown on standing.</span></p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Hereditary coproporphyria"
        },
        {
          "id": 2,
          "text": "Acute intermittent porphyria"
        },
        {
          "id": 3,
          "text": "Porphyria cutanea tarda"
        },
        {
          "id": 4,
          "text": "Variegate porphyria"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>An adult female with intermittent abdominal pain, nausea, vomiting, constipation, bilateral lower limb numbness with elevated urine ALA and porphobilinogen is most likely to have <strong>acute intermittent porphyria </strong>(AIP).</p>\n<p>AIP is a type of <strong>hepatic porphyria</strong> characterized by neurovisceral symptoms. AIP is caused by a defect in <strong>hydroxymethylbilane synthase, </strong>which converts prophobilinogen to hydroxymethylbilane. Patients present with <strong>abdominal pain</strong>, <strong>tachycardia</strong>, <strong>hypertension</strong> and <strong>peripheral neuropathy</strong>. There is increased plasma and urinary ALA and prophobilinogen. <strong>Darkening </strong>of<strong> urine</strong> on exposure to air also occurs. </p>\n<p>Other options:</p>\n<p>Options A and D: <strong>Hereditary coproporphyria</strong> and<strong> variegate porphyria</strong> present with both photosensitivity and neurovisceral symptoms. The porphyrin intermediates appearing in urine help differentiate the two diseases. </p>\n<p>Option C: <strong>Porphyria cutanea tarda </strong>presents with blistering photosensitivity with vesicles and bullae formation. </p><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0725",
      "difficulty": "easy"
    },
    {
      "text": "Which  of the following is not a hepatic porphyria?",
      "choices": [
        {
          "id": 1,
          "text": "Variegate porphyria"
        },
        {
          "id": 2,
          "text": "Acute intermittent porphyria"
        },
        {
          "id": 3,
          "text": "Porphyria cutanea tarda"
        },
        {
          "id": 4,
          "text": "Erythropoietic protoporphyria"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Erythropoietic protoporphyria</strong> is <strong>not</strong> a type of <strong>hepatic porphyria. </strong></p>\n<p>Porphyrias are classified into<strong> erythropoietic</strong> and <strong>hepatic</strong> porphyrias, based on the location of accumulation of heme pathway intermediates:</p>\n<ol>\n<li><strong>Erythropoietic porphyrias:</strong>\n<ol>\n<li>The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n<li>They are characterized by <strong>cutaneous symptoms</strong> and appear in early childhood.</li>\n<li>Examples: Congenital erythropoietic porphyria, <strong>erythropoietic protoporphyria</strong>, X-linked protoporphyria</li>\n</ol>\n</li>\n<li><strong>Hepatic porphyrias: </strong>\n<ol>\n<li>The overproduction of heme pathway intermediates occurs primarily in<strong> </strong>the liver.</li>\n<li><strong>Acute hepatic porphyrias</strong><span> are characterised by <strong>neurologic symptoms</strong> and present acutely. </span>Examples: Acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, ALA dehydratase deficient porphyria</li>\n<li><strong>Chronic hepatic porphyrias</strong><span> </span><span>present in adulthood with <strong>photosensitivity</strong>. Example: Porphyria cutanea tarda</span></li>\n</ol>\n</li>\n</ol><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0722",
      "difficulty": "medium"
    },
    {
      "text": "An  infant presented with delayed eruption of her teeth. An image of her teeth are shown below. She also has history of blisters over the face, hands and feet on exposure to sunlight since the first week of birth. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Congenital erythropoietic porphyria"
        },
        {
          "id": 2,
          "text": "Porphyria cutanea tarda"
        },
        {
          "id": 3,
          "text": "Erythropoietic protoporphyria"
        },
        {
          "id": 4,
          "text": "Acute intermittent porphyria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>An infant with delayed eruption and reddish discoloration of teeth, and blisters over sun-exposed areas suggests a diagnosis of <strong>c</strong><strong>ongenital erythropoietic porphyria</strong>. </p>\n<p>Congenital erythropoietic porphyria, also is known as <strong>Gunther's disease</strong>, is an <strong>autosomal recessive</strong> porphyria. There is <strong>uroporphyrinogen III synthase</strong> deficiency, leading to <strong>uroporphyrin I</strong> and <strong>coproporphyrin I</strong> accumulation in teeth, bone marrow, erythrocyte, plasma urine and feces.</p>\n<p>Infants present with <strong>port wine urine</strong> or pink stained diapers, <strong>severe cutaenous hypersensitivity,</strong> and reddish-brown teeth known as <strong>erythrodontia</strong>. When illuminated with UV light, the teeth show <strong>reddish fluorescence</strong>. It may cause non-immune hydrops in utero or shortly after birth in severe cases. </p><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/84ee81e8c4a044d2bbf77d64997ccb45.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0703",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following porphyria is caused by a mutation of ALA synthase-2?",
      "choices": [
        {
          "id": 1,
          "text": "Acute intermittent porphyria"
        },
        {
          "id": 2,
          "text": "Congenital erythropoietic porphyria"
        },
        {
          "id": 3,
          "text": "X- linked protoporphyria"
        },
        {
          "id": 4,
          "text": "Erythropoietic protoporphyria"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>X-linked protoporphyria </strong>is caused by a mutation of<strong> ALA synthase-2. </strong></p>\n<p>X-linked Protoporphyria is caused by a <strong>gain-of-function </strong>mutation, leading to the<strong> </strong>increased activity<strong> </strong>of ALA synthase-2. This results in <strong>increased ALA</strong><strong> synthesis</strong>. Due to the saturation of iron, <strong>protoporphyrins</strong> are not converted to heme and thus protoporphyrins <strong>accumulate</strong>.</p>\n<p>ALA synthase-2 mutation<strong> </strong>is also seen in<strong> X-linked sideroblastic anemia. </strong>However, this is not a porphyria. X-linked sideroblastic anemia is due to <strong>loss-of-function </strong>mutation, leading to<strong> </strong>decreased activity<strong> </strong>of ALA synthase-2 and <strong>decreased protoporphyrin synthesis</strong>.</p><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0728",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following enzyme is defective in variegate porphyria?",
      "choices": [
        {
          "id": 1,
          "text": "Coproporphyrinogen oxidase"
        },
        {
          "id": 2,
          "text": "Protoporphyrinogen oxidase"
        },
        {
          "id": 3,
          "text": "Uroporphyrinogen III synthase"
        },
        {
          "id": 4,
          "text": "Uroporphyrinogen decarboxylase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Protoporphyrinogen oxidase</strong> enzyme is defective in <strong>variegate porphyria.</strong></p>\n<p>Variegate porphyria is an autosominal dominant porphyria. <strong>Protoporphyrinogen IX</strong> accumulates in the urine. Patients present with acute attacks of<strong> abdominal pain</strong> and <strong>peripheral neuropathy</strong>. <strong>Cutaneous photosensitivity</strong> is also seen. </p><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0709",
      "difficulty": "medium"
    },
    {
      "text": "Carbon monoxide is released in which of the following reactions?",
      "choices": [
        {
          "id": 1,
          "text": "Conversion of biliverdin to bilirubin"
        },
        {
          "id": 2,
          "text": "Conversion of heme to biliverdin"
        },
        {
          "id": 3,
          "text": "Conversion of bilirubin to bilirubin monoglucuronide"
        },
        {
          "id": 4,
          "text": "Conversion of bilirubin monoglucuronide to bilirubin diglucuronide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The conversion of <strong>heme </strong>to <strong>biliverdin</strong> produces <strong>carbon monoxide</strong>.</p>\n<p><strong>Heme oxygenase</strong> catabolises <strong>heme</strong> to <strong>biliverdin</strong>. <strong>Carbon monoxide </strong>and <strong>ferric iron</strong> are released in the process. This is the only source of endogenous carbon monoxide in the body. <strong>Biliverdin reductase</strong> further converts biliverdin to bilirubin in an NADPH-dependent reaction.<strong> </strong>Iron produced from this reaction is stored as <strong>ferritin</strong>.</p>\n<p>The process of heme catabolism occurs in the<strong> microsomal </strong>fraction (endoplasmic reticulum) of <strong>reticuloendothelial cells</strong>.</p>\n<p><strong>Note: </strong>1 g of hemoglobin produces 35 mg of bilirubin. About 250-350 mg bilirubin is produced daily in the adults.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/10986ef1a529432fafed16feee599e5ex1280x2558.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0747",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the site of bilirubin conjugation within the cell?",
      "choices": [
        {
          "id": 1,
          "text": "Cytoplasm"
        },
        {
          "id": 2,
          "text": "Endoplasmic reticulum"
        },
        {
          "id": 3,
          "text": "Mitochondria"
        },
        {
          "id": 4,
          "text": "Golgi apparatus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>endoplasmic reticulum</strong> is the site for the <strong>conjugation</strong> of <strong>bilirubin.</strong></p>\n<p>Hepatocytes convert bilirubin to a <strong>polar form</strong> by a process called <strong>conjugation</strong>. <strong>UDP-glucuronic acid</strong> acts as a glucuronyl donor in this reaction. It initially produces <strong>bilirubin monoglucuronide. </strong>This is subsequently converted to <strong>bilirubin diglucuronide </strong>which is excreted in bile. Conjugation is catalysed by the enzyme <strong>glucuronyl transferase</strong>, which is present in the endoplasmic reticulum.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/654595a16eb449379a8f2ec45d4666cax1280x2025.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0735",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the rate-limiting step for hepatic bilirubin metabolism?",
      "choices": [
        {
          "id": 1,
          "text": "Transport of bilirubin with albumin"
        },
        {
          "id": 2,
          "text": "Uptake of bilirubin by liver"
        },
        {
          "id": 3,
          "text": "Conjugation of bilirubin"
        },
        {
          "id": 4,
          "text": "Secretion of conjugated bilirubin into the bile"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The <strong>secretion </strong>of <strong>conjugated bilirubin</strong> into the bile is the <strong>rate-limiting</strong> <strong>step</strong> for hepatic bilirubin metabolism.</p>\n<p>The secretion of conjugated bilirubin into the bile occurs by an <strong>active transport</strong> mechanism, which involves <strong>multidrug resistance-associated protein 2 </strong>(MRP-2),<strong> </strong>also called<strong> multispecific organic anion transporter </strong>(MOAT). It is located in the plasma membrane of the bile canaliculi.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d8ec7f47e417453fb9481fb1e0eea995x1280x2025.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0757",
      "difficulty": "hard"
    },
    {
      "text": "In a patient with jaundice which of the following tests can be used to determine serum bilirubin?",
      "choices": [
        {
          "id": 1,
          "text": "Ehrlich's test"
        },
        {
          "id": 2,
          "text": "Van den Bergh test"
        },
        {
          "id": 3,
          "text": "Hay's test"
        },
        {
          "id": 4,
          "text": "Benedict's test"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Van den Bergh test</strong> can be used to determine the <strong>serum bilirubin</strong> level in a patient with jaundice.</p>\n<p>Van den Bergh reaction is a <strong>colorimetric method</strong> to measure serum bilirubin. It is based on the formation of <strong>red-purple</strong> <strong>azodipyrroles</strong> when <strong>diazotized sulfanilic acid</strong> reacts with <strong>bilirubin</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Clinical condition</strong></td>\n<td><strong>Reaction with reagent</strong></td>\n<td><strong>Interpretation</strong></td>\n</tr>\n<tr>\n<td>Normal serum</td>\n<td>No reaction</td>\n<td>Negative</td>\n</tr>\n<tr>\n<td>High <strong>conjugated</strong> bilirubin<br />Eg: Obstructive jaundice</td>\n<td>Reacts in the absence of methanol</td>\n<td><strong>Direct</strong> positive</td>\n</tr>\n<tr>\n<td>High <strong>unconjugated</strong> bilirubin<br />Eg: Hemolytic anemia</td>\n<td>Reacts in the presence of methanol</td>\n<td><strong>Indirect</strong> positive</td>\n</tr>\n<tr>\n<td>High <strong>conjugated </strong>and<strong> unconjugated</strong> bilirubin<br />Eg: Hepatic jaundice</td>\n<td>Reacts strongly both with and without methanol</td>\n<td><strong>Biphasic</strong> reaction</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p>Option A: <strong>Ehrlich's test </strong>is used to determine urinary and fecal<strong> </strong>urobilinogen.</p>\n<p>Option C: <strong>Hay's test </strong>is used for bile salts in the urine.</p>\n<p>Option D: <strong>Benedict's test</strong> is used to detect the presence of reducing sugars.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0751",
      "difficulty": "medium"
    },
    {
      "text": "A 65 year old man was admitted with generalised weakness, easy fatigability, itching and jaundice since 1 month. On examination, he was emaciated and had scratch marks all over the body. A mass was palpable in the upper abdomen. Which of the following can be seen on Van den Bergh reaction?",
      "choices": [
        {
          "id": 1,
          "text": "Direct positive"
        },
        {
          "id": 2,
          "text": "Indirect positive"
        },
        {
          "id": 3,
          "text": "Biphasic reaction"
        },
        {
          "id": 4,
          "text": "Negative"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Generalised weakness, easy fatigability, itching and jaundice with a palpable upper abdominal mass is suggestive of <strong>pancreatic malignancy</strong> leading to <strong>obstructive jaundice</strong>. This gives a <strong>direct positive</strong> result on Van den Bergh reaction.</p>\n<p>In obstructive jaundice, <strong>obstruction</strong> of the <strong>biliary tree</strong> causes regurgitation of conjugated bilirubin into the blood. Patients present with itching, jaundice and<strong> pale coloured stools</strong>.</p>\n<p>Van den Bergh reaction is a <strong>colorimetric method</strong> to measure the serum bilirubin level. It is based on the formation of <strong>red azodipyrroles</strong> when <strong>diazotized sulfanilic acid</strong> reacts with <strong>bilirubin</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Clinical condition</strong></td>\n<td><strong>Reaction with reagent</strong></td>\n<td><strong>Interpretation</strong></td>\n</tr>\n<tr>\n<td>Normal serum</td>\n<td>No reaction</td>\n<td>Negative</td>\n</tr>\n<tr>\n<td>High <strong>conjugated</strong> bilirubin<br />eg: <strong>Obstructive jaundice</strong></td>\n<td>Reacts in the absence of methanol</td>\n<td><strong>Direct</strong> positive</td>\n</tr>\n<tr>\n<td>High <strong>unconjugated</strong> bilirubin<br />eg: Hemolytic anemia</td>\n<td>Reacts in the presence of methanol</td>\n<td><strong>Indirect</strong> positive</td>\n</tr>\n<tr>\n<td>High <strong>conjugated </strong>and<strong> unconjugated</strong> bilirubin<br />eg: Hepatic jaundice</td>\n<td>Reacts strongly both with and without methanol</td>\n<td><strong>Biphasic</strong> reaction</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div dir=\"ltr\" align=\"left\"> </div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3516",
      "difficulty": "medium"
    },
    {
      "text": "An adult male patient presents with yellow discolouration of the sclera. There was a history of recurrent mild jaundice since childhood. His lab values are mentioned below. A liver biopsy was performed which revealed normal liver architecture with coarse granular black pigmentation. The mutation of which protein is involved in the following condition?<div class='question-desc-html'><p>AST: 20 U/L , ALT: 18 U/L</p>\n<p>Total bilirubin : 4.2mg/dl, Conjugated bilirubin: 3.6 mg/dl</p>\n<p>Total protein: 6.4 g/dL, normal A/G ratio.</p>\n<p>Urine: Normal porphyrin levels.</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "OATP1B1"
        },
        {
          "id": 2,
          "text": "BSEP"
        },
        {
          "id": 3,
          "text": "MRP-3"
        },
        {
          "id": 4,
          "text": "MRP-2"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Yellow discolouration of the sclera with coarse granular black pigmentation of the liver is suggestive of <strong>Dubin–Johnson syndrome</strong>, characterized by a mutation in the<strong> MRP-2 </strong>protein.<strong><br /></strong></p>\n<p>Dubin–Johnson syndrome is an <strong>autosomal recessive</strong> disorder with predominantly<strong> conjugated hyperbilirubinemia</strong>. It is due to a defect in the <strong>active</strong> <strong>transport </strong>of <strong>bilirubin</strong> across the canalicular membrane, due to a mutation in the MRP-2 protein.<strong> </strong>It is also known as <strong>black liver jaundice</strong> due to the accumulation of a<strong> dark pigment</strong>,<strong> </strong>derived from epinephrine metabolites, in the lysosomes of <strong>centrilobular hepatocytes</strong>. <strong>Bromosulpthalein</strong> test on plasma shows 2 peaks.</p>\n<p>Option A: <strong>OATP1B1</strong> and<strong> OATP1B3</strong> are mutated in<strong> </strong>Rotor syndrome.<strong> </strong>It is due to defective bilirubin excretion and causes conjugated hyperbilirubinemia.</p>\n<p>Option B:<strong> BSEP</strong> protein is mutated in<strong> </strong>progressive familial intrahepatic cholestasis (PFIC type-2) and benign recurrent intrahepatic cholestasis (BRIC-2).</p>\n<p>Option C: <strong>MRP-3</strong> is mutated in<strong> </strong>PFIC type-3.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8518b44c87334f41b2aca086ef0d4abex1280x2025.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Hyperbilirubinemia- Causes</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Predominantly Unconjugated Hyperbilirubinemia&nbsp;</strong></td>\n<td><strong>Conjugated hyperbilirubinemia</strong></td>\n</tr>\n<tr>\n<td>\n<p>Excess production of bilirubin</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Hemolytic anemias</p>\n</td>\n<td>\n<p>Biliary tract obstruction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Resorption of blood from internal hemorrhage (e.g., alimentary tract bleeding, hematomas)</p>\n</td>\n<td>\n<p>&nbsp;Biliary tract diseases like primary biliary cirrhosis and primary sclerosing cholangitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ineffective erythropoiesis (e.g., pernicious anemia, thalassemia)</p>\n</td>\n<td>\n<p>Dubin Johnson syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Reduced hepatic uptake</p>\n</td>\n<td>\n<p>Rotor syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Drug interference with membrane carrier systems</p>\n</td>\n<td>Benign recurrent intrahepatic cholestasis</td>\n</tr>\n<tr>\n<td>\n<p>Some cases of Gilbert syndrome</p>\n</td>\n<td>Progressive familial intrahepatic cholestasis</td>\n</tr>\n<tr>\n<td>\n<p>Impaired bilirubin conjugation</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Physiologic jaundice of the newborn (decreased UGT1A1 activity, decreased excretion)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Breast milk jaundice (&beta;-glucuronidases in milk)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Genetic deficiency of UGT1A1 activity (Crigler-Najjar syndrome types I and II)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Gilbert syndrome</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Diffuse hepatocellular disease (e.g., viral or drug-induced hepatitis, cirrhosis)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Hereditary Hyperbilirubinemias</h3><table>\n<tbody>\n<tr>\n<td><strong>Disorder</strong></td>\n<td><strong>Inheritance</strong></td>\n<td><strong>Defects in bilirubin metabolism</strong></td>\n<td><strong>Clinical course</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Unconjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type I</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Absent UGT1A1 activity</p>\n</td>\n<td>\n<p>Fatal in the neonatal period</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type II</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Generally mild,</p>\n<p>occasional kernicterus</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Gilbert syndrome</p>\n</td>\n<td>\n<p>AR (common)</p>\n<p>AD (occasional)</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Conjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Dubin-Johnson syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Impaired biliary excretion of bilirubin glucuronides due to a mutation in canalicular multidrug resistance protein 2 (MRP2)</p>\n</td>\n<td>\n<p>Innocuous with black pigmentation of liver</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Rotor syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased hepatic uptake and storage</p>\n<p>Decreased biliary excretion</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0758",
      "difficulty": "medium"
    },
    {
      "text": "A young adult presents with yellowish discolouration of the skin and sclerae for the last 3 days. He is otherwise asymptomatic. He had a viral fever one week ago which has now resolved. Investigations reveal unconjugated hyperbilirubinemia. Which of the following is true regarding this patient's condition?",
      "choices": [
        {
          "id": 1,
          "text": "BSEP protein is mutated"
        },
        {
          "id": 2,
          "text": "Active transport of bilirubin is impaired due to MRP-2 mutation"
        },
        {
          "id": 3,
          "text": "Promoter defect of UGT1A1 enzyme is the most common cause"
        },
        {
          "id": 4,
          "text": "Missense mutation of transferase enzyme is the most common cause"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>A young adult with a <strong>short</strong> history of <strong>jaundice</strong> following a period of <strong>stress</strong> (viral fever) with <strong>unconjugated hyperbilirubinemia</strong> likely has <strong>Gilbert syndrome</strong>. Gilbert syndrome most commonly occurs due to <strong>promoter defect </strong>of the<strong> UGT1A1 </strong>enzyme.</p>\n<p>Gilbert syndrome is caused by a defect in the promoter region of the gene coding for the <strong>UDP-glucuronosyl transferase </strong>(UGT1A1) enzyme. This results in a variable rate of<strong> </strong>transcription of the normal enzyme. UGT1A1 activity is <strong>reduced </strong>to <strong>10-33% </strong>of normal.<strong> </strong>It presents with periods of mild <strong>unconjugated hyperbilirubinemia</strong> with other liver function tests being normal. The disorder is precipitated by <strong>stress</strong>,<strong> alcohol</strong> and <strong>reduced caloric intake</strong>.</p>\n<p>Liver histology shows <strong>increased lipofuscin pigment. </strong>It responds well to <strong>phenobarbitone</strong>. Gilbert's syndrome doesn't require treatment. The bilirubin levels may fluctuate over time, and patients may occasionally have jaundice, which usually resolves on its own with no ill effects.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/04d6d42dfe35415b8315f67a12794f64x1280x2025.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Hereditary Hyperbilirubinemias</h3><table>\n<tbody>\n<tr>\n<td><strong>Disorder</strong></td>\n<td><strong>Inheritance</strong></td>\n<td><strong>Defects in bilirubin metabolism</strong></td>\n<td><strong>Clinical course</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Unconjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type I</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Absent UGT1A1 activity</p>\n</td>\n<td>\n<p>Fatal in the neonatal period</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type II</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Generally mild,</p>\n<p>occasional kernicterus</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Gilbert syndrome</p>\n</td>\n<td>\n<p>AR (common)</p>\n<p>AD (occasional)</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Conjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Dubin-Johnson syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Impaired biliary excretion of bilirubin glucuronides due to a mutation in canalicular multidrug resistance protein 2 (MRP2)</p>\n</td>\n<td>\n<p>Innocuous with black pigmentation of liver</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Rotor syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased hepatic uptake and storage</p>\n<p>Decreased biliary excretion</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0761",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false regarding jaundice?",
      "choices": [
        {
          "id": 1,
          "text": "Urine bilirubin is absent in hemolytic jaundice"
        },
        {
          "id": 2,
          "text": "Urine urobilinogen is increased in obstructive jaundice"
        },
        {
          "id": 3,
          "text": "Criggler-Najjar syndrome presents with unconjugated hyperbilirubinemia"
        },
        {
          "id": 4,
          "text": "Hepatocellular jaundice can have normal or decreased urine urobilinogen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Urine <strong>urobilinogen</strong> is <strong>not increased</strong> in <strong>obstructive jaundice.</strong></p>\n<p>Obstructive jaundice has the following features:</p>\n<ul>\n<li><strong>Absent urinary urobilinogen: </strong>In complete obstruction of the biliary tree, conjugated bilirubin cannot enter the intestine. Thus it is not metabolized by the intestinal flora and urobilinogen is not formed.</li>\n<li><strong>Increased serum direct bilirubin</strong>: Due to obstruction in the biliary tree, the bilirubin conjugates diffuse into the blood causing <strong>conjugated hyperbilirubinemia</strong>.</li>\n<li><strong>Increased urine bilirubin</strong>: Conjugated bilirubin is water-soluble and thus appears in the urine in excess amounts.</li>\n</ul>\n<p>Option A: <strong>Urine bilirubin </strong>is absent in hemolytic jaundice because unconjugated bilirubin is not water-soluble.</p>\n<p>Option C: <strong>Criggler-Najjar syndrome</strong>, due to absent UGT1A1 activity, presents with raised unconjugated bilirubin.</p>\n<p>Option D: <strong>Hepatocellular jaundice </strong>can have decreased urine urobilinogen if micro-obstruction occurs due to swollen, damaged hepatocytes.</p><hr><h3>Related Pearl: Types of Jaundice</h3><table>\n<tbody>\n<tr>\n<td><strong>Type of jaundice</strong></td>\n<td><strong>Serum bilirubin</strong></td>\n<td><strong>Urine Urobilinogen</strong></td>\n<td><strong>Urine bilirubin</strong></td>\n</tr>\n<tr>\n<td>Pre-hepatic</td>\n<td>&uarr; Indirect</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&uarr;</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp;-</td>\n</tr>\n<tr>\n<td>Hepatic</td>\n<td>&uarr; Direct and indirect</td>\n<td>&nbsp; Normal/&nbsp;&darr;</td>\n<td>&nbsp; &nbsp; &nbsp; +/-</td>\n</tr>\n<tr>\n<td>Post-hepatic</td>\n<td>&uarr; Direct</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp;+</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6960",
      "difficulty": "medium"
    }
  ]
}